Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05605509 | RP-6306 in Patients With Advanced Cancer | PHASE2 | COMPLETED | 28 | — | — | May 24, 2023 | Feb 5, 2026 | Feb 6, 2026 | 6 | Canada |
| Arm | Type | Description |
|---|---|---|
| RP-6306 + Gemcitabine | ACTIVE_COMPARATOR | - |
| RP-6306 + FOLFIRI | ACTIVE_COMPARATOR | - |
| RP-6306 + Trastuzumab | ACTIVE_COMPARATOR | - |
| RP-6306 + RP-3500 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| RP-6306 | DRUG | Dose and schedule will be assigned at enrolment |
| Gemcitabine | DRUG | Dose and schedule will be assigned at enrolment |
| FOLFIRI Protocol | DRUG | Irinotecan Leucovorin FU |
| Trastuzumab | DRUG | standard doses q3weekly |
| RP-3500 | DRUG | Dose and schedule will be assigned at enrolment |
Inclusion Criteria: * Patients must have histologically confirmed cancer, that is advanced/metastatic/recurrent or unresectable, for which no curative therapy exists, and be eligible for one or more of the open cohorts * All patients must have a formalin fixed paraffin embedded tissue block (from p...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |